Skip to main content

Market Overview

Recap: Schrodinger Q1 Earnings



Shares of Schrodinger (NASDAQ:SDGR) decreased 1.4% in pre-market trading after the company reported Q1 results.

Quarterly Results

Earnings per share increased 100.00% over the past year to $0.00, which beat the estimate of ($0.16).

Revenue of $32,127,000 higher by 22.74% year over year, which beat the estimate of $29,230,000.

Looking Ahead

Schrödinger reaffirmed FY21 sales guidance of $124 million-$142 million.

How To Listen To The Conference Call

Date: May 11, 2021

Time: 08:30 AM

ET Webcast URL:

Price Action

Company's 52-week high was at $117.00

Company's 52-week low was at $46.27

Price action over last quarter: down 9.26%

Company Description

Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. Schrodinger generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.


Related Articles (SDGR)

View Comments and Join the Discussion!

Posted-In: BZI-RecapsEarnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at